Sanofi teams with virtual reality biotech on oral Dupixent successor

Sanofi teams with virtual reality biotech on oral Dupixent successor

Source: 
Endpoints
snippet: 

Sanofi’s latest bet on a potential Dupixent sequel is a preclinical pill developed by a British small-cap that specializes in virtual reality chemistry.

The French pharma rolled the dice Monday on an up to $500 million deal with C4X Discovery. The milestone-heavy, $8 million upfront agreement will license to Sanofi a small molecule the discovery biotech developed to block the cytokine IL-17 — a potential oral treatment for psoriasis and other inflammatory conditions.